Bio-Gene TechnologyASX:BGT -10.53% EV-to-FCF is -2.05 as of Jul. 02, 2026. The stock has 2 warning signs investors should review. Among 333 Biotechnology companies, Bio-Gene Technology ranks worse than 300300% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bio-Gene Technology's Enterprise Value is A$5.38 Mil.
Bio-Gene Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.62 Mil. Therefore, Bio-Gene Technology's EV-to-FCF for today is -2.05.
The historical rank and industry rank for Bio-Gene Technology's EV-to-FCF or its related term are showing as below:
ASX:BGT'
s EV-to-FCF Range Over the Past 10 Years
Min: -20.73 Med: -4.5 Max: 0.09
Current: -2.5
During the past 8 years, the highest EV-to-FCF of Bio-Gene Technology was 0.09. The lowest was -20.73. And the median was -4.50.
ASX:BGT's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 15.57
vs ASX:BGT: -2.50
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio-Gene Technology's PE Ratio (TTM) for today is calculated as:
Bio-Gene Technology's share price for today is A$0.017.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bio-Gene Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bio-Gene Technology EV-to-FCF Related Terms
Bio-Gene Technology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bio-Gene Technology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Gene Technology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gene Technology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bio-Gene Technology's EV-to-FCF falls into.
Bio-Gene Technology's current Enterprise Value is A$5.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bio-Gene Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$-2.62 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Gene Technology (ASX:BGT) has a EV-to-FCF of -2.05 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bio-Gene Technology and its competitors. According to the industry distribution chart, Bio-Gene Technology ranks #999999 out of 333 companies in the Biotechnology industry.
Is Bio-Gene Technology's EV-to-FCF too high?
Bio-Gene Technology's current EV-to-FCF is -2.05. Based on the distribution chart, Bio-Gene Technology ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Gene Technology's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Gene Technology ranks #999999 out of 333 companies for EV-to-FCF. This places Bio-Gene Technology in the lower half of its industry. The industry median EV-to-FCF is 15.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.57, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bio-Gene Technology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Gene Technology's current EV-to-FCF is -2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current EV-to-FCF of -2.05. The current EV-to-FCF is -2.05. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current EV-to-FCF is -2.05 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BGT has been successfully added to your 